Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose provides a source of calories and hydration, preventing ketosis and promoting glycogen deposition. Sodium chloride maintains extracellular fluid volume and electrolyte balance.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Treatment of fluid and electrolyte depletion,Provision of caloric intake in patients requiring parenteral nutrition,Correction of hypoglycemia,Maintenance fluid therapy
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Adult: Intravenous infusion at a rate determined by clinical condition, typically 100-200 m L/hour for maintenance; maximum infusion rate 25 g/hour (500 m L/hour). Dose individualized based on fluid, electrolyte, and glucose needs.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Dextrose: <15 minutes due to rapid cellular uptake and metabolism; sodium and chloride: no defined half-life as electrolytes are homeostatically regulated.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Dextrose is rapidly metabolized via glycolysis and the Krebs cycle; sodium chloride is not metabolized but excreted renally.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal; dextrose is metabolized to CO2 and water; sodium and chloride are excreted renally with >90% reabsorption under normal conditions.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Dextrose: negligible; sodium and chloride: not protein bound.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Dextrose: approximately 0.2 L/kg (total body water); sodium and chloride: distribute into extracellular fluid (approx 0.2 L/kg).
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
100% for intravenous route; not applicable for oral/other routes.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
No specific dose adjustment for dextrose; monitor fluid and electrolyte balance. In severe renal impairment (e GFR <30 m L/min/1.73 m²), restrict volume as needed to avoid fluid overload and hyperkalemia when combined with sodium chloride.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No specific adjustment for Child-Pugh class; monitor glucose and fluid status. Caution in severe hepatic failure due to risk of hyperglycemia and fluid retention.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Weight-based dosing: Intravenous infusion at 4-8 mg/kg/min for glucose provision; typical maintenance fluid rates: 100 m L/kg/day for first 10 kg, 50 m L/kg/day for next 10 kg, 20 m L/kg/day for each additional kg. Individualize based on age, weight, and clinical status.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Monitor for fluid overload, hyperglycemia, and electrolyte disturbances. Use lower initial infusion rates (e.g., 50-100 m L/hour) and adjust based on renal function and cardiovascular status. Avoid excessive sodium load in patients with hypertension or heart failure.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
Not for use in patients with intracranial or intraspinal hemorrhage, or in those with known hypersensitivity to corn or corn products (dextrose source).
None.
Risk of hyperglycemia, especially in diabetic patients,Risk of fluid overload, especially in patients with renal impairment or heart failure,Electrolyte imbalances (e.g., hypernatremia, hyperchloremia) with excessive administration,Use with caution in patients with hepatic disease, as dextrose may exacerbate encephalopathy
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hyperglycemia,Hypernatremia,Intracranial or intraspinal hemorrhage,Known hypersensitivity to corn or corn products,Severe hypokalemia (can worsen with dextrose infusion)
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No specific food interactions. However, as this solution provides dextrose (sugar) and sodium, patients with diabetes or salt-restricted diets should be monitored. Avoid concurrent intake of high-sugar or high-salt foods without medical advice.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Dextrose and sodium chloride are physiological components; no evidence of teratogenicity at standard doses. Maternal glucose control important in first trimester to avoid hyperglycemia-related congenital anomalies. Intravenous administration may be necessary in third trimester for fluid maintenance. No direct fetal toxicity.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Dextrose and sodium chloride are normal constituents of breast milk. Intravenous infusion does not alter milk composition significantly. M/P ratio not applicable. Considered compatible with breastfeeding.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
No dosing adjustment required solely for pregnancy. However, increased plasma volume in pregnancy may require careful monitoring of fluid balance to avoid overload. Adjust rate and volume based on clinical status, not pregnancy per se.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Use with caution in patients with congestive heart failure, renal impairment, or conditions causing sodium retention. Monitor serum glucose and electrolytes, especially in diabetic patients or those receiving parenteral nutrition. Avoid in patients with hyperglycemia, hyponatremia, or fluid overload. Do not administer simultaneously with blood products due to risk of hemolysis. Inspect for particulate matter and discoloration before use; discard if present.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
Inform your healthcare provider if you have diabetes, high blood pressure, heart or kidney disease, or fluid retention.,Report any signs of allergic reaction such as rash, itching, swelling, or difficulty breathing.,Tell your doctor if you experience headache, confusion, muscle cramps, or swelling of hands/ankles.,This solution provides sugar and salt; discuss any dietary restrictions with your doctor.,Do not use the solution if it is cloudy, discolored, or contains particles.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose provides a source of calories and hydration, preventing ketosis and promoting glycogen deposition. Sodium chloride maintains extracellular fluid volume and electrolyte balance.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER is: Adult: Intravenous infusion at a rate determined by clinical condition, typically 100-200 m L/hour for maintenance; maximum infusion rate 25 g/hour (500 m L/hour). Dose individualized based on fluid, electrolyte, and glucose needs.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER is classified as Category A/B. Dextrose and sodium chloride are physiological components; no evidence of teratogenicity at standard doses. Maternal glucose control important in first trimester to avoid hyperglyc. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.